Bictegravir
BIC Phase 2 Study: BIC + FTC/TAF vs DTG + FTC/TAF
Original article :
Sax PE. Lancet HIV 2017; 4:e154-e160
Last update :
29/03/2017
Dr Anton Pozniak
Chelsea and Westminster Hospital
London, UK
Design :
BIC: 75 mg QDµ
DTG: 50 mg QD
Objective :
- % HIV RNA < 50 c/mL at W24
Baseline characteristics and patient disposition
HIV RNA < 50 c/ml (ITT, snapshot )
CD4 increase at W48 (mean)
- BIC: + 258/mm3 vs DTG: + 192/mm3
Adverse events, %
- 1 patient in the BIC + FTC/TAF group with a past history of urticaria and atopic dermatitis discontinued study drug after W24 due to urticaria
Back to Table of Contents